Vanguard Group
EFTR

Vanguard Group’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Vanguard Group’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,070
Closed -$7.27K – 4454
2024
Q2 		$7.27K Sell
25,070
-67,395
-73% -$160K ﹤0.01% 4400
2024
Q1 		$1.33M Buy
92,465
+69,488
+302% +$831K ﹤0.01% 3720
2023
Q4 		$268K Buy
22,977
+6,816
+42% +$91.4K ﹤0.01% 4178
2023
Q3 		$242K Sell
16,161
-76
-0.5% -$1.32K ﹤0.01% 4218
2023
Q2 		$337K Hold
16,237
– – ﹤0.01% 4216
2023
Q1 		$143K Sell
16,237
-925
-5% -$11.2K ﹤0.01% 4368
2022
Q4 		$183K Hold
17,162
– – ﹤0.01% 4322
2022
Q3 		$245K Sell
17,162
-3,510
-17% -$68.8K ﹤0.01% 4386
2022
Q2 		$734K Hold
20,672
– – ﹤0.01% 4181
2022
Q1 		$2.07M Buy
20,672
+25
+0.1% +$3.32K ﹤0.01% 3943
2021
Q4 		$4.27M Buy
+20,647
New +$4.79M ﹤0.01% 3695

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group's EFTR Position: Q3 2024 in Review

Vanguard Group sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 25,070 shares — an estimated $7.27K sold.

Vanguard Group first reported a position in EFTR in Q4 2021 and held it in 11 quarters. The position peaked at $4.27M in Q4 2021. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

  • Vanguard Group reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Vanguard Group sold 25,070 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $7.27K.
  • Vanguard Group first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
  • Vanguard Group's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $4.27M in Q4 2021.
  • 3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.